Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Bahrain has been experiencing steady growth in recent years.
Customer preferences: Bahrain has a high prevalence of hypertension, which has led to an increased demand for anti-hypertensive drugs. As a result, the market has seen a rise in the number of drug options available to consumers, with many opting for combination therapies. Additionally, there is a growing preference for generic drugs due to their lower cost.
Trends in the market: The market has seen a shift towards the use of newer drugs such as angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs). This is due to the fact that these drugs have been shown to have fewer side effects compared to older drugs such as beta-blockers. Furthermore, there has been an increased focus on the development of fixed-dose combination drugs that combine two or more anti-hypertensive drugs in a single pill. This has been driven by the need to simplify treatment regimens and improve patient adherence.
Local special circumstances: Bahrain has a well-established healthcare system that provides universal coverage to its citizens. This has led to an increased demand for anti-hypertensive drugs, as more people are able to access healthcare services. Additionally, the government has implemented several initiatives aimed at promoting healthy lifestyles and reducing the prevalence of hypertension in the population. This has included the introduction of a sugar tax and the implementation of public health campaigns.
Underlying macroeconomic factors: Bahrain has a small but well-developed economy that is heavily dependent on the oil and gas industry. However, the government has been working to diversify the economy and promote growth in other sectors such as healthcare. This has led to an increased focus on the development of the pharmaceutical industry, which has contributed to the growth of the anti-hypertensive drugs market. Furthermore, Bahrain has a high-income population that is willing to spend on healthcare, which has also contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
